Health Condition 1: I251- Atherosclerotic heart disease of native coronary artery Health Condition 2: I259- Chronic ischemic heart disease, unspecified
Conditions
Interventions
Intervention1: NIL: NIL
Sponsors
Strand Life Sciences Private Limited
Eligibility
Inclusion criteria
Inclusion criteria: Inclusion criteria (Affected Arm - cohort 1 and 2) 1. Individuals 40 years or above with confirmed diagnosis of obstructive or non-obstructive CAD, with clinical information confirming CAD and other available clinical parameters (age of onset, method of diagnosis, phenotypic characteristics, any information on repeated occurrence, associated SOC test results) 2.Individuals from the general population of any sex and race. 3. Individuals who has the ability to understand and willing to sign the Informed consent form 4.Willingness to contribute 20-23ml blood Inclusion criteria (Control Arm (1) - Cohort 3) 1.Healthy individuals 40 years or above with no symptoms or predisposition to the disease - no history of hypertension, diabetes, BMI below 30, no history of use of smoking or smokeless tobacco, no history of dyslipidemia or hyperlipidemia. Inclusion criteria (Control arm (2) - Cohort 4) 1.Individuals 40 years or above with high cholesterol, dyslipidemia or hyperlipidemia or BMIabove 30 but with confirmed diagnosis of no CAD (this cohort is included to identify the protective variant, if any for CAD) 2.Individuals who may be or are users of tobacco products (smoke and smokeless). 3.Individuals who may be or are experiencing a sedentary lifestyle like lack of physical activity & exercise (pertaining to age).
Exclusion criteria
Exclusion criteria: Exclusion Criteria (Affected Arm) 1.Patients not consenting or unable to give an informed written consent 2.Patients not meeting the inclusion criteria or judged by the investigator to be unsuitable for inclusion into the study Exclusion criteria (Control Arm 1 (Cohort 3)) 1.Individuals whose BMI is greater than 30 (Obesity) 2.Individuals with diabetes, hypertension and high cholesterol, dyslipidemia or hyperlipidemia with risk of developing CAD 3.Individuals who are habitual users of tobacco products (smoke and smokeless). Individuals experiencing sedentary lifestyle like lack of physical activity & exercise (pertaining to age). Exclusion criteria (Control Arm 2 (Cohort 4)) 1.Patients not consenting or unable to give an informed written consent 2.Patients not meeting the inclusion criteria or judged by the investigator to be unsuitable for inclusion into the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Outcome of this study is to identify the molecular biomarkers that help in the early detection of CAD & help in identification of high risk populations. The study will also enable identification of variants which can be later used for drug targeting for CAD.Timepoint: At baseline | — |
Secondary
| Measure | Time frame |
|---|---|
| Outcome of this study is to identify the molecular biomarkers that help in the early detection of CAD & help in identification of high risk populations. The study will also enable identification of variants which can be later used for drug targeting for CAD.Timepoint: At baseline | — |
Countries
India
Contacts
Public ContactDr Vamsi Veeramachaneni
Strand Life Sciences Private Limited
Outcome results
None listed